Results 111 to 120 of about 6,658 (202)

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS

, 2017
\ua9 2017 John Wiley & Sons, Ltd. Poly(adenosine diphosphate ribose) polymerases (PARPs) are multifunctional proteins which play a role in many cellular processes.
Maxwell RJ, Bawn CM, Thomas HD, Curtin NJ, Galler M, Wilson I, Newell DR, Almeida GS, Kyle S   +8 more
core  

Redox-neutral synthesis of azepane-fused spiroindolenines <i>via</i> Sc(OTf)₃-catalyzed cascade [1,5]-hydride transfer/cyclization. [PDF]

RSC Adv
Zhang L, Chen J, Tang G, Chen M, Fan X, Wang Y, Fan Y, Wen H, Li X, Xie X.   +9 more
europepmc   +1 more source

Mitochondrial superoxide sustains a senescence-like phenotype in PARP- inhibited ovarian cancer cells by stabilizing HIF1α. [PDF]

Redox Biol
Yang T, Bu W, Xue X, Wu X, Zhou Y, Chen Y, Li Y, Zhang J, Li P, Shen F, Shi Y, Shao C.   +11 more
europepmc   +1 more source

BCLX_L blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer. [PDF]

Signal Transduct Target Ther
Venkatachalam A, Strathman AR, Hou X, Correia C, Meng XW, McGehee CD, Balczewski EA, Duffield LN, Rossman OK, Wong C, Dai H, Hurley RM, Wagner JM, Singh S, Flatten KS, Peterson KL, Schneider PA, De Lorenzo SB, Larson MC, Oberg AL, Wahner Hendrickson AE, Wu X, Pandey A, Li H, Weroha SJ, Kaufmann SH.   +25 more
europepmc   +1 more source

Synthetic lethality between PBRM1 deficiency and PARP inhibitors: exploiting G2/M checkpoint arrest in colorectal cancer. [PDF]

Mol Med
Islam MT, Quan H, Chen S, Xu Z, Guo M, Wang Z.   +5 more
europepmc   +1 more source

PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies. [PDF]

Front Cell Dev Biol
Ouhajjou A, Mazouji O, Nejjari C, Incitti R, Mansour H.   +4 more
europepmc   +1 more source

Liquid biopsy: a new window on the BRCA genes. [PDF]

ESMO Open
Incorvaia L, Gristina V, Pepe F, Bazan Russo TD, Santoni M, Mujacic C, Curigliano G, Malapelle U, Capoluongo ED, Russo A.   +9 more
europepmc   +1 more source

Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis. [PDF]

Front Oncol
Liang L, Yang B, Wu Y, Liu JL, Liu R, Sun L.   +5 more
europepmc   +1 more source

Safety and tolerability of PARP inhibitors in cancer patients: a network meta-analysis of randomized controlled trials. [PDF]

BMC Cancer
Wei C, Liu S, Hu J, Cao B, Liu B.
europepmc   +1 more source

Rucaparib and its Usage Areas

Journal of Experimental and Basic Medical Sciences, 2020
openaire   +1 more source